Rosetta Genomics Ltd - ESG Rating & Company Profile powered by AI
Alternative companies in the scoring peer group for Rosetta Genomics Ltd are displayed below. This page includes a questions and answers section about Rosetta Genomics Ltd. The report of Rosetta Genomics Ltd uses data points from across the internet as well as from public documents by Rosetta Genomics Ltd.
Rosetta Genomics Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | Rosetta Genomics Ltd | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Rosetta Genomics Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Rosetta Genomics Ltd report the average age of the workforce?
Sign up for free to unlockDoes Rosetta Genomics Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Rosetta Genomics Ltd offer flexible work?
Sign up for free to unlockDoes Rosetta Genomics Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Rosetta Genomics Ltd conduct supply chain audits?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Rosetta Genomics Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose water use targets?
Sign up for free to unlockDoes Rosetta Genomics Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Rosetta Genomics Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Rosetta Genomics Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Rosetta Genomics Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Rosetta Genomics Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Rosetta Genomics Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Rosetta Genomics Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose its waste policy?
Sign up for free to unlockDoes Rosetta Genomics Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose energy use targets?
Sign up for free to unlockDoes Rosetta Genomics Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Rosetta Genomics Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Rosetta Genomics Ltd
These potential risks are based on the size, segment and geographies of the company.
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.